Back to Registry

CJC-1295

Also known as: CJC-1295 DAC, Modified GRF(1-29)

FDA Banned (Category B)

Molecular Formula

C152 H252 N44 O42

Molecular Weight

3,367.9 Da (without DAC) / 3,647.28 Da (with DAC)

Half-Life

30 min–2 hours (without DAC) / 5.8–8.1 days (with DAC)

Sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Clinical Applications & Evidence

Mechanism of Action

The peptide functions as a highly selective agonist for the GHRH receptor located on the cellular membrane of somatotroph cells in the anterior pituitary. Activation of this G-protein coupled receptor initiates an adenylate cyclase signaling cascade, increasing intracellular cyclic adenosine monophosphate (cAMP) and triggering the rapid exocytosis of pre-packaged growth hormone secretory vesicles into the systemic circulation.

Investigated Uses

  • Growth hormone deficiency
  • Age-related GH decline
  • Body composition improvement
  • Recovery and tissue repair
  • Sleep quality enhancement
Moderate Clinical Data

Regulatory & Safety Status

FDA Status

FDA Banned (Category B)

WADA / Athletic Status

Prohibited in Competition

Known Side Effects

FlushingHeadacheWater retentionInjection site reactionsNumbness/tingling

Contraindications

  • Active malignancy
  • Pituitary disorders
  • Pregnancy

Drug Interactions

  • May potentiate effects of exogenous GH
  • Glucocorticoids may blunt GH response

Citations & Clinical Trials

PubMed Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Drug Testing and Analysis Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation FDA FDA Briefing Document: Pharmacy Compounding Advisory Committee (December 2024)